A Study of YM178 in Patients With Symptomatic Overactive Bladder

A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.

Inclusion Criteria:

• Patients over 20 years suffering from overactive bladder

Exclusion Criteria:

• Pregnant and breastfeeding women
• Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study